Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts

Burgess, M. A., Bolejack, V., Schuetze, S., Van Tine, B. A., Attia, S., Riedel, R. F., Hu, J. S., Davis, L. E., Okuno, S. H., Priebat, D. A., Movva, S., Reed, D. R., D'Angelo, S. P., Lazar, A. J., Keung, E. Z. Y., Reinke, D. K., Baker, L. H., Maki, R. G., Patel, S., Tawbi, H. A. H. (May 2019) Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO).

URL: https://ascopubs.org/toc/jco/37/15
Item Type: Conference or Workshop Item (Poster)
Subjects: diseases & disorders > cancer > drugs and therapies > Immunotherapy
diseases & disorders > cancer > cancer types > sarcoma
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matthew Dunn
Date: May 2019
Date Deposited: 18 Oct 2019 18:56
Last Modified: 18 Oct 2019 19:09
URI: https://repository.cshl.edu/id/eprint/38616

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving